Compare PD & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | SGP |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.0M | 650.9M |
| IPO Year | 2019 | N/A |
| Metric | PD | SGP |
|---|---|---|
| Price | $8.70 | $18.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $12.63 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.1M | 39.5K |
| Earning Date | 05-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $492,546,000.00 | N/A |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $67.46 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $17.60 |
| 52 Week High | $17.45 | $30.56 |
| Indicator | PD | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 32.86 |
| Support Level | $6.08 | $17.60 |
| Resistance Level | $16.74 | $26.29 |
| Average True Range (ATR) | 0.56 | 1.42 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 50.24 | 15.72 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.